Univ. of Minnesota v. Gilead Sciences: Consent Judgment After 2,012-Day Patent Fight
The Regents of the University of Minnesota sued Gilead Sciences over US8815830, a patent covering nucleosides with antiviral and anticancer activity. After the Federal Circuit affirmed a PTAB finding of invalidity, the parties entered a consent judgment ending the case — a litigation spanning more than five and a half years.
A University Patent on Antiviral Nucleosides Meets an IPR Invalidity Finding
The Regents of the University of Minnesota filed this patent infringement action against Gilead Sciences, Inc. in the Northern District of California on October 23, 2017, asserting US Patent No. 8,815,830 (Application No. 14/229,292), which covers nucleosides with antiviral and anticancer activity. Gilead Sciences is a major biopharmaceutical company whose product portfolio includes antiviral therapeutics. The University of Minnesota is a public research institution and the holder of US8815830.
The case was resolved by consent judgment on April 27, 2023. The recorded basis of termination is Consent Judgment. The docket order reflects that the parties stipulated to dismissal with prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), with each party to bear its own fees and costs. The stipulation followed the Federal Circuit's March 6, 2023 affirmance of the Patent Trial and Appeal Board's decision in IPR2017-01712, which found US8815830 invalid for anticipation, and the University's stated decision not to petition for certiorari.
The case ran for 2,012 days — a duration consistent with complex pharmaceutical patent disputes involving parallel IPR proceedings. The Federal Circuit's affirmance of the PTAB invalidity finding appears to have been the proximate driver of the parties' agreed resolution. The specific terms of the consent judgment beyond the fee-bearing provision and dismissal with prejudice are not disclosed in the available record.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 2012 days
days from filing to consent judgment — over 5.5 years of active litigation
US8815830 — Nucleosides with Antiviral and Anticancer Activity
Any company developing or commercialising nucleoside analogue therapeutics — particularly antivirals or anticancer agents — should be aware that US8815830 has been found invalid for anticipation by the PTAB, with that finding affirmed by the Federal Circuit. While this patent is no longer an active enforcement risk, related family members, continuation applications, and co-pending University of Minnesota filings in the same nucleoside chemistry space may still present clearance questions. FTO analysis should extend beyond US8815830 to the full University of Minnesota nucleoside portfolio.
Official order — verbatim text
The stipulation recites that the Federal Circuit affirmed the PTAB's invalidity finding under IPR2017-01712 on March 6, 2023, and that the University of Minnesota elected not to petition for certiorari — indicating the invalidity of US8815830 for anticipation is final. The parties then jointly moved for resolution, and the recorded basis of termination is Consent Judgment; the docket order is styled as a stipulated dismissal with prejudice under Rule 41(a)(1)(A)(ii) with each side bearing its own fees and costs.
Consent judgment: what the agreed resolution means for both parties
What a consent judgment means in patent litigation
A consent judgment is a court-entered judgment on terms agreed by the parties, making it binding and final. It differs from a unilateral court ruling in that both sides jointly move for its entry. Here, the stipulation was submitted under Rule 41(a)(1)(A)(ii) and dismisses all claims and counterclaims with prejudice. The specific terms of the agreement beyond what is recorded in the stipulation are not disclosed in the available record.
Binding court-entered judgmentMinnesota exits with US8815830 invalidated and no cost recovery
The University of Minnesota's asserted patent, US8815830, was found invalid for anticipation by the PTAB in IPR2017-01712, a finding affirmed by the Federal Circuit. The University indicated it would not seek certiorari. The consent judgment forecloses any further pursuit of the infringement claims in this action. Each party bears its own fees and costs, meaning no monetary award flows to the University from this proceeding.
Patent invalidated; no recoveryGilead obtains dismissal with prejudice — patent cannot be re-asserted
Gilead Sciences benefits from a dismissal with prejudice of all claims and counterclaims. Combined with the PTAB invalidity finding affirmed by the Federal Circuit, Gilead faces no further exposure under US8815830 in this action. Each party bears its own fees and costs under the stipulation. The specific terms of the consent judgment beyond these recorded elements are not disclosed in the available record.
Full dismissal with prejudiceInvalidated nucleoside patent reduces IP barrier for antiviral developers
US8815830's invalidity finding, now affirmed at the Federal Circuit level, removes this patent as an enforcement tool across the antiviral and anticancer nucleoside space. Companies active in nucleoside analogue therapeutics — including antivirals such as HCV and HIV treatments — may find this outcome relevant when assessing freedom-to-operate exposure. The affirmance at the Federal Circuit level means the invalidity finding carries substantial weight for the sector.
Reduced FTO risk for nucleoside developersFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Regents of the University of Minnesota | Company | Public research university — holder of US8815830 covering antiviral/anticancer nucleosidesSearch in Eureka ↗ |
| Defendant | Gilead Sciences, Inc. | Company | Gilead Sciences, Inc. — biopharmaceutical company focused on antiviral therapeuticsSearch in Eureka ↗ |
| Plaintiff counsel | Brian J. Slovut | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Christopher W. Henry | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Edward R. Gates | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Erin E. Conti | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Gerald Bill Hrycyszyn | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | James W. Morando | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | John R. Marti | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Katherine N. Arnold | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Kenneth A. Liebman | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Marie A. Mckiernan | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Michael A. Albert | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff counsel | Timothy E. Grimsrud | Attorney | Counsel for Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff law firm | Dorsey & Whitney LLP | Law Firm | Representing Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff law firm | Faegre Baker Daniels LLP | Law Firm | Representing Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff law firm | Faegre Drinker Biddle & Reath LLP | Law Firm | Representing Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff law firm | Farella Braun & Martel LLP | Law Firm | Representing Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins LLP | Law Firm | Representing Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff law firm | University of Minnesota | Law Firm | Representing Regents of the University of MinnesotaSearch in Eureka ↗ |
| Plaintiff law firm | Wolf, Greenfield & Sacks PC | Law Firm | Representing Regents of the University of MinnesotaSearch in Eureka ↗ |
| Defendant counsel | Adam K. Mortara | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Alison G. Wheeler | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Barbara P. Berens | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Carrie L. Zochert | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Erin K. Fogarty Lisle | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Faye Paul | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Glen E. Summers | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Irene Inkyu Yang | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | J. Scott Mcbride | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Katherine G. Minarik | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark S Ouweleen | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Nevin Merrill Gewertz | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Nosson D Knobloch | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Rebecca Taylor Horwitz | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Sue Wang | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Bartlit Beck Herman Palenchar & Scott LLP | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Bartlit Beck LLP | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Berens and Miller, PA | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Munger, Tolles & Olson LLP | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Sidley Austin LLP | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Northern District CourtSearch in Eureka ↗ |
R&D signals in the antiviral nucleoside patent space
Forward-looking patent intelligence derived from the University of Minnesota v. Gilead Sciences dispute — tracking portfolio activity, filing trends, and white-space opportunities in nucleoside antiviral chemistry.
University of Minnesota's nucleoside filing activity post-US8815830
With US8815830 invalidated, attention shifts to the University of Minnesota's broader nucleoside and antiviral patent portfolio. Research universities typically maintain active prosecution pipelines; continuation filings, divisional applications, and new chemistry claims in adjacent nucleoside scaffolds may represent ongoing IP risk for companies in this therapeutic class. Mapping the full University portfolio is a high-priority intelligence task for antiviral drug developers.
University nucleoside portfolioFiling trends in nucleoside analogue antiviral therapeutics
Nucleoside analogues remain one of the most actively patented drug classes globally, underpinning treatments for HCV, HIV, influenza, and SARS-CoV-2. Patent filing volumes in this space have increased with pandemic-era antiviral development. Understanding which assignees are building claims around novel nucleoside scaffolds — and where claim density is highest — helps R&D teams anticipate freedom-to-operate constraints before entering clinical development.
Nucleoside antiviral filing trendsGilead Sciences' patent position in nucleoside antiviral chemistry
Gilead Sciences holds an extensive patent portfolio in nucleoside and nucleotide prodrug chemistry, covering antivirals including sofosbuvir and remdesivir. Following its successful IPR challenge to US8815830, Gilead's IP posture in this class remains strong. Monitoring Gilead's prosecution activity and new filings in nucleoside scaffolds provides competitive intelligence for companies seeking to develop non-infringing antiviral compounds or identify licensing opportunities.
Gilead antiviral IP positionClaim white space near invalidated nucleoside scaffold of US8815830
The anticipation-based invalidation of US8815830 may open claim space in nucleoside chemistry that was previously encumbered. R&D teams developing novel nucleoside analogues should assess whether the prior art cited in IPR2017-01712 also constrains adjacent chemical structures, or whether differentiated scaffold designs can support new, defensible patent filings in antiviral and anticancer nucleoside chemistry.
Nucleoside claim white spaceSimilar antiviral nucleoside patent cases in N.D. California & Federal Circuit
Explore related patent infringement actions involving antiviral nucleoside compounds litigated in the Northern District of California and resolved at the Federal Circuit.
What this case signals for the antiviral nucleoside IP landscape
A university patent invalidated via IPR and affirmed at the Federal Circuit — key signals for pharma IP strategy.
IPR remains a decisive weapon against university-held pharmaceutical patents
This case demonstrates that inter partes review can be an effective route to invalidity even against patents held by research universities with strong prosecution histories. Gilead's IPR petition in IPR2017-01712 succeeded at the PTAB and survived Federal Circuit review, ultimately driving the consent judgment. Companies facing similar university assertions should assess IPR viability early.
Federal Circuit affirmance of anticipation elevates the invalidity finding's authority
An anticipation finding affirmed by the Federal Circuit carries significant precedential weight. For companies operating in the nucleoside analogue space, US8815830 is no longer an active enforcement risk. Portfolio managers and FTO analysts should update clearance opinions to reflect this outcome and monitor the University of Minnesota's remaining nucleoside-related filings.
Regents v Gilead — key questions answered
The case ended by consent judgment on April 27, 2023. The recorded basis of termination is Consent Judgment. The docket order reflects a stipulated dismissal with prejudice under Rule 41(a)(1)(A)(ii), with each party bearing its own fees and costs. The stipulation followed the Federal Circuit's March 6, 2023 affirmance of the PTAB's invalidity finding for US8815830.
The asserted patent is US Patent No. 8,815,830 (Application No. 14/229,292), assigned to the Regents of the University of Minnesota. It covers nucleosides with antiviral and anticancer activity. The PTAB found it invalid for anticipation in IPR2017-01712, a finding affirmed by the Federal Circuit on March 6, 2023.
The Patent Trial and Appeal Board found US8815830 invalid for anticipation in IPR2017-01712. The Federal Circuit affirmed that decision on March 6, 2023. Following that affirmance, the University of Minnesota stated it would not petition for certiorari, and the parties stipulated to a consent judgment ending the district court litigation.
Under the stipulation recorded in the available docket, each party bears its own attorneys' fees and costs. No fee award was made to either side. The specific terms of the consent judgment beyond this provision are not disclosed in the available record.
Based on the available record, US8815830 was found invalid for anticipation by the PTAB in IPR2017-01712, and the Federal Circuit affirmed that finding on March 6, 2023. The University of Minnesota elected not to petition for certiorari. The consent judgment dismisses all claims with prejudice. US8815830 is therefore not an active enforcement tool based on these proceedings.
PatSnap Eureka searches patents and litigation data to answer instantly.